Evidence map›Paper›PMID 40309932›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Genome-wide association analysis identifies APOE as a mitophagy modifier in Lewy body disease.

Xu Hou, Michael G Heckman, Fabienne C Fiesel, Shunsuke Koga, Alexandra I Soto-Beasley, Jens O Watzlawik, Jing Zhao, Rebecca R Valentino, Patrick W Johnson, Launia J White and 9 more

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. International journal of molecular sciences · 2025
    Article
  6. Review
  7. Genome-wide association analysis identifies APOE as a mitophagy modifier in Lewy body disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Xu HouDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Michael G HeckmanDivision of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida, USA.
Fabienne C FieselDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Shunsuke KogaDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Alexandra I Soto-BeasleyDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Jens O WatzlawikDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Jing ZhaoDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Rebecca R ValentinoDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Patrick W JohnsonDivision of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida, USA.
Launia J WhiteDivision of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida, USA.
Zachary S QuicksallDivision of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, Florida, USA.
Joseph S ReddyDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.
Jose BrasDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, USA.
Rita GuerreiroDepartment of Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, USA.
Na ZhaoDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Guojun BuDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Owen A RossDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Wolfdieter SpringerDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.

Funding

Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI ALISON M GOATE, DAVID M. HOLTZMAN · 2021 to 2026
$42.0M
Project: Predicting PhenoconversionU19AG071754 · NIA · WASHINGTON UNIVERSITY · PI Bradley F Boeve, Yo-El S Ju · 2021 to 2026
$41.2M
Research Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$33.5M
Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
Utilization of proteomics and lipidomics to identify modifiers of LBDU54NS110435 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J · 2019 to 2023
$14.5M
Neuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Project 2: Identifying genes and Pathways that impact Tau Toxicity in FTDU54NS100693 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2016 to 2020
$6.2M
Bio-RaPID: Biomarkers and Rates of Progression In Dementia.R01AG089380 · NIA · MAYO CLINIC JACKSONVILLE · PI DAY, GREGORY SCOTT · 2024 to 2025
$4.1M
ApoE isoform-specific therapy for Alzheimer diseaseRF1AG046205 · NIA · MAYO CLINIC JACKSONVILLE · PI ZHAO, NA · 2019 to 2019
$3.1M
Molecular mechanisms of PINK1-PRKN directed mitochondrial quality controlRF1NS085070 · NINDS · MAYO CLINIC JACKSONVILLE · PI SPRINGER, WOLFDIETER · 2019 to 2019
$2.8M
Mitochondrial Sirtuin 3 in Parkinson's diseaseR01NS110085 · NINDS · MAYO CLINIC JACKSONVILLE · PI MCLEAN, PAMELA J, SPRINGER, WOLFDIETER · 2019 to 2023
$2.5M
Alzheimer's Association AARF-22-973152American Brain FoundationAmerican Parkinson Disease Association Center for Advanced Research at Mayo Clinic JacksonvilleCongressionally Directed Medical Research Programs W81XWH-17-1-0248Congressionally Directed Medical Research Programs W81XWH-17-1-0249Florida Department of Health-Ed, Ethel Moore Alzheimer's Disease Research Program 22A05Florida Department of Health-Ed, Ethel Moore Alzheimer's Disease Research Program 22A07Mangurian Foundation Lewy Body Dementia Program at Mayo ClinicMayo Clinic Center for Biomedical DiscoveryMayo Clinic Office of Research Equity, Inclusion, and DiversityMayo Clinic Robert and Arlene Kogod Center on AgingNIA NIH HHS P30 AG062677NIA NIH HHS P30AG062677NIA NIH HHS R01 AG056366NIA NIH HHS R01AG056366NIA NIH HHS R01 AG087165NIA NIH HHS R01AG087165NIA NIH HHS R01 AG089380NIA NIH HHS R01AG089380NIA NIH HHS R56 AG062556NIA NIH HHS R56AG062556NIA NIH HHS RF1 AG046205NIA NIH HHS RF1AG046205NIA NIH HHS U19 AG069701NIA NIH HHS U19AG069701NIA NIH HHS U19 AG071754NIA NIH HHS U19AG071754NINDS NIH HHS P50 NS072187NINDS NIH HHS P50NS072187NINDS NIH HHS R01 NS078086NINDS NIH HHS R01NS078086NINDS NIH HHS R01 NS110085NINDS NIH HHS R01NS110085NINDS NIH HHS RF1 NS085070NINDS NIH HHS RF1NS085070NINDS NIH HHS U01 NS100620NINDS NIH HHS U01NS100620NINDS NIH HHS U54 NS100693NINDS NIH HHS U54NS100693NINDS NIH HHS U54 NS110435NINDS NIH HHS U54NS110435Ted Turner and FamilyThe Little Family FoundationThe Michael J. Fox Foundation for Parkinson's ResearchThe Ted Nash Long Life Foundation
6 · The paper itself

Abstract

introductionPhosphorylated ubiquitin (p-S65-Ub) is generated during PINK1-PRKN mitophagy as a specific marker of mitochondrial damage. Despite the widespread deposition of p-S65-Ub in aged and diseased human brain, the genetic contribution to its accumulation remains unclear.

methodsTo identify novel mitophagy regulators, we performed a genome-wide association study using p-S65-Ub level as a quantitative trait in 1012 autopsy-confirmed Lewy body disease (LBD) samples.

resultsWe identified a significant genome-wide association with p-S65-Ub for rs429358 (apolipoprotein E ε4 [APOE4]) and a suggestive association for rs6480922 (ZMIZ1). APOE4 was associated with higher p-S65-Ub levels and greater neuropathological burden. Functional validation in mouse and human induced pluripotent stem cell (iPSC) models confirmed APOE4-mediated mitophagy alterations. Intriguingly, ZMIZ1 rs6480922 was associated with lower p-S65-Ub levels, reduced neuropathological load, and increased brain weight, indicating a potential protective role. DISCUSSION: Our findings underscore the importance of mitochondrial quality control in LBD pathogenesis and nominate regulators that may contribute to disease risk or resilience. HIGHLIGHTS: p-S65-Ub levels were used as a quantitative marker of mitochondrial damage. A GWAS identified two genetic variants that modify mitophagy in LBD autopsy brain. APOE4 was associated with increased p-S65-Ub accumulation and neuropathology. APOE4 altered mitophagy via pathology-dependent and pathology-independent mechanisms. ZMIZ1 was linked to reduced p-S65-Ub and neuropathology indicative of protection.

Indexed as

Apolipoprotein E4Apolipoproteins ELewy Body DiseaseMitophagyAgedAged, 80 and overAnimalsBrainFemaleGenome-Wide Association StudyHumansInduced Pluripotent Stem CellsMaleMiceMitochondriaPolymorphism, Single NucleotideApolipoprotein E4Apolipoproteins EUbiquitinautophagyGWASmitochondriaParkinParkinson's diseasephosphorylated ubiquitinPINK1PRKNubiquitinZMIZ1

Identifiers

PMID40309932
PMCPMC12044520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.